Updates On Anti-Amyloid Monoclonal Antibodies For Ad In Phase Iii Trials

Updates on anti-amyloid monoclonal antibodies for AD in Phase III trials

Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials

Advancing amyloidosis care: developments in anti-amyloid monoclonal antibodies

VJHemOnc – Video Journal of Hematology & HemOnc

Second generation of anti-amyloid monoclonal antibodies for Alzheimer's disease

Anti-amyloid combination strategies in Alzheimer's disease

An Update on Anti-Amyloid Treatments for Alzheimer's Disease

Penn Memory Center

Monoclonal Antibodies Targeting Amyloid for Alzheimer Disease

Next-generation anti-amyloid therapies: prioritizing selectivity

Phase II study of lecanemab in early AD

Development of a new anti-amyloid antibody PMN310 for the treatment of Alzheimer’s disease

Important developments in dementia: biomarkers & clinical trials

AD/PD™️ 2024 – Highlights research on earlier treatment with anti-amyloid immunotherapies

Springer Healthcare IME

Topline donanemab results: most positive Phase III data to date

Updates in pharmacological treatment of Alzheimer’s disease: lecanemab, donanemab and gantenerumab

Experimental Alzheimer's drug shows benefits in phase 3 trial

ARC TALKS Webinar: Clinical Trial Updates for the AL Community

Amyloidosis Research Consortium (ARC)

Phase III AHEAD 3-45 trial of lecanemab for preclinical Alzheimer’s disease

Future direction for anti-amyloid immunotherapies

Is amyloid load a valid surrogate endpoint for AD clinical trials?

Testing anti-amyloid therapies in preclinical Alzheimer's disease